OSDDMalaria:OSDD Malaria Meeting Sydney 2012

From OpenWetWare

(Difference between revisions)
Jump to: navigation, search
m (Potential Invitees)
m (Invited)
Line 55: Line 55:
* [http://en.wikipedia.org/wiki/Richard_Anthony_Jefferson Richard Jefferson], CAMBIA
* [http://en.wikipedia.org/wiki/Richard_Anthony_Jefferson Richard Jefferson], CAMBIA
* [http://www.policycures.org/staff.html Mary Moran], Policy Cures
* [http://www.policycures.org/staff.html Mary Moran], Policy Cures
* [http://www.wehi.edu.au/faculty_members/professor_alan_cowman Alan Cowman]
===Potential Invitees===
===Potential Invitees===

Revision as of 19:58, 1 February 2012

Malaria Home        OSM So Far        Compound Series        Links        Open Source Research Home        Tech Ops        FAQ       


Open Source Drug Discovery for Malaria - February 24th 2012

There will be a one-day meeting on Open Source Drug Discovery for Malaria at The University of Sydney, February 2012.

Location Information

The meeting will take place on the main Camperdown campus of The University of Sydney.


9 a.m. start Welcome by Mat Todd and opening remarks by Mary O'Kane, NSW Chief Scientist.
Morning session 1: What is the current status of drug discovery and development for malaria?
Morning session 2: What is the scientific and economic case for open source drug discovery?
Afternoon session 1: What are the most significant types of drugs needed for the treatment of malaria?
Afternoon session 2: Which compounds should we pursue? Who should do it? How?
5 p.m. Drinks and dinner

Sessions will broadly address these questions:


  • How is it best to share chemical and biological data in an open project?
  • What technical barriers prevent open science?
  • Which licence governs an open source drug discovery project?
  • What psychological/professional barriers are there to open science?
  • Is there a danger that open source drug discovery can be hijacked by people taking all the data and patenting them?
  • Who might participate?
  • Who will fund later stages such as clinical trials?
  • Who will manufacture open drugs?


  • Is the GSK arylpyrrole set the best set of compounds to start with?
  • What other compounds are promising starting point? Who might want to work on those compounds?
  • For hit-to-lead, what data are typically needed, and from which assays? What criteria do we apply to compounds as they progress through such assays?

To suggest questions/sessions of interest, please modify this page directly (getting an OWW account is very easy) or contact Mat Todd.



Potential Invitees

Possibly interesting list maintained here


Personal tools